Surgical Science Sweden AB (publ)
Surgical Science Sweden AB (publ) Fundamental Analysis
Surgical Science Sweden AB (publ) (SUSRF) shows moderate financial fundamentals with a PE ratio of 20.54, profit margin of 6.73%, and ROE of 1.54%. The company generates $1.0B in annual revenue with strong year-over-year growth of 12.25%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 50.0/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze SUSRF's fundamental strength across five key dimensions:
Efficiency Score
WeakSUSRF struggles to generate sufficient returns from assets.
Valuation Score
ExcellentSUSRF trades at attractive valuation levels.
Growth Score
ModerateSUSRF shows steady but slowing expansion.
Financial Health Score
ExcellentSUSRF maintains a strong and stable balance sheet.
Profitability Score
ModerateSUSRF maintains healthy but balanced margins.
Key Financial Metrics
Is SUSRF Expensive or Cheap?
P/E Ratio
SUSRF trades at 20.54 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, SUSRF's PEG of -0.50 indicates potential undervaluation.
Price to Book
The market values Surgical Science Sweden AB (publ) at 0.32 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 19.92 times EBITDA. This signals the market has high growth expectations.
How Well Does SUSRF Make Money?
Net Profit Margin
For every $100 in sales, Surgical Science Sweden AB (publ) keeps $6.73 as profit after all expenses.
Operating Margin
Core operations generate 7.63 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $1.54 in profit for every $100 of shareholder equity.
ROA
Surgical Science Sweden AB (publ) generates $1.43 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Surgical Science Sweden AB (publ) generates limited operating cash flow of $79.60M, signaling weaker underlying cash strength.
Free Cash Flow
Surgical Science Sweden AB (publ) produces free cash flow of $39.16M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.77 in free cash annually.
FCF Yield
SUSRF converts 2.86% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
20.54
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.50
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.32
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.38
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
4.07
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.02
vs 25 benchmark
ROA
Return on assets percentage
0.01
vs 25 benchmark
ROCE
Return on capital employed
0.02
vs 25 benchmark
How SUSRF Stacks Against Its Sector Peers
| Metric | SUSRF Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 20.54 | 28.25 | Better (Cheaper) |
| ROE | 1.54% | 780.00% | Weak |
| Net Margin | 6.73% | -20122.00% (disorted) | Weak |
| Debt/Equity | 0.00 | 0.30 | Strong (Low Leverage) |
| Current Ratio | 4.07 | 4.66 | Strong Liquidity |
| ROA | 1.43% | -14687.00% (disorted) | Weak |
SUSRF outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Surgical Science Sweden AB (publ)'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
537.82%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
188.40%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
131.43%
Industry Style: Defensive, Growth, Innovation
High Growth